Activation of AMPK stimulates neurotensin secretion in neuroendocrine cells

Jing Li, Jun Song, Heidi L. Weiss, Todd Weiss, Courtney Townsend, B. Mark Evers

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    AMP-activated protein kinase (AMPK), a critical fuel-sensing enzyme, regulates the metabolic effects of various hormones. Neurotensin (NT) is a 13-amino acid peptide predominantly localized in enteroendocrine cells of the small bowel and released by fat ingestion. Increased fasting plasma levels of pro-NT (a stable NT precursor fragment produced in equimolar amounts relative to NT) are associated with an increased risk of diabetes, cardiovascular disease, and mortality; however, the mechanisms regulating NT release are not fully defined. We previously reported that inhibition of the mammalian target of rapamycin (mTOR) complex 1 (mTORC1) increases NT secretion and gene expression through activation of the MEK/ERK pathway. Here, we show that activation of AMPK increases NT secretion from endocrine cell lines (BON and QGP-1) and isolated mouse crypt cells enriched for NT-positive cells. In addition, plasma levels of NT increase in mice treated with 5-aminoimidazole-4-carboxamide riboside, a pharmacologic AMPK activator. Small interfering RNA-mediated knockdown of AMPKα decrease, whereas overexpression of the subunit significantly enhances, NT secretion from BON cells treated with AMPK activators or oleic acid. Similarly, small interfering RNA knockdown of the upstream AMPK kinases, liver kinase B1 and Ca2+ calmodulin-dependent protein kinase kinase 2, also attenuate NT release and AMPK phosphorylation. Moreover, AMPK activation increases NT secretion through inhibition of mTORC1 signaling. Together, our findings show that AMPK activation enhances NT release through inhibition of mTORC1 signaling, thus demonstrating an important cross talk regulation for NT secretion.

    Original languageEnglish (US)
    Pages (from-to)26-36
    Number of pages11
    JournalMolecular Endocrinology
    Volume30
    Issue number1
    DOIs
    StatePublished - Jan 1 2016

    Fingerprint

    Neuroendocrine Cells
    Neurotensin
    AMP-Activated Protein Kinases
    Small Interfering RNA
    Phosphotransferases
    Enteroendocrine Cells
    Calcium-Calmodulin-Dependent Protein Kinases
    Endocrine Cells
    MAP Kinase Signaling System
    Oleic Acid

    ASJC Scopus subject areas

    • Molecular Biology
    • Endocrinology

    Cite this

    Activation of AMPK stimulates neurotensin secretion in neuroendocrine cells. / Li, Jing; Song, Jun; Weiss, Heidi L.; Weiss, Todd; Townsend, Courtney; Mark Evers, B.

    In: Molecular Endocrinology, Vol. 30, No. 1, 01.01.2016, p. 26-36.

    Research output: Contribution to journalArticle

    Li, Jing ; Song, Jun ; Weiss, Heidi L. ; Weiss, Todd ; Townsend, Courtney ; Mark Evers, B. / Activation of AMPK stimulates neurotensin secretion in neuroendocrine cells. In: Molecular Endocrinology. 2016 ; Vol. 30, No. 1. pp. 26-36.
    @article{4943d3d974f7497bb04f42d3886830b2,
    title = "Activation of AMPK stimulates neurotensin secretion in neuroendocrine cells",
    abstract = "AMP-activated protein kinase (AMPK), a critical fuel-sensing enzyme, regulates the metabolic effects of various hormones. Neurotensin (NT) is a 13-amino acid peptide predominantly localized in enteroendocrine cells of the small bowel and released by fat ingestion. Increased fasting plasma levels of pro-NT (a stable NT precursor fragment produced in equimolar amounts relative to NT) are associated with an increased risk of diabetes, cardiovascular disease, and mortality; however, the mechanisms regulating NT release are not fully defined. We previously reported that inhibition of the mammalian target of rapamycin (mTOR) complex 1 (mTORC1) increases NT secretion and gene expression through activation of the MEK/ERK pathway. Here, we show that activation of AMPK increases NT secretion from endocrine cell lines (BON and QGP-1) and isolated mouse crypt cells enriched for NT-positive cells. In addition, plasma levels of NT increase in mice treated with 5-aminoimidazole-4-carboxamide riboside, a pharmacologic AMPK activator. Small interfering RNA-mediated knockdown of AMPKα decrease, whereas overexpression of the subunit significantly enhances, NT secretion from BON cells treated with AMPK activators or oleic acid. Similarly, small interfering RNA knockdown of the upstream AMPK kinases, liver kinase B1 and Ca2+ calmodulin-dependent protein kinase kinase 2, also attenuate NT release and AMPK phosphorylation. Moreover, AMPK activation increases NT secretion through inhibition of mTORC1 signaling. Together, our findings show that AMPK activation enhances NT release through inhibition of mTORC1 signaling, thus demonstrating an important cross talk regulation for NT secretion.",
    author = "Jing Li and Jun Song and Weiss, {Heidi L.} and Todd Weiss and Courtney Townsend and {Mark Evers}, B.",
    year = "2016",
    month = "1",
    day = "1",
    doi = "10.1210/me.2015-1094",
    language = "English (US)",
    volume = "30",
    pages = "26--36",
    journal = "Molecular Endocrinology",
    issn = "0888-8809",
    publisher = "The Endocrine Society",
    number = "1",

    }

    TY - JOUR

    T1 - Activation of AMPK stimulates neurotensin secretion in neuroendocrine cells

    AU - Li, Jing

    AU - Song, Jun

    AU - Weiss, Heidi L.

    AU - Weiss, Todd

    AU - Townsend, Courtney

    AU - Mark Evers, B.

    PY - 2016/1/1

    Y1 - 2016/1/1

    N2 - AMP-activated protein kinase (AMPK), a critical fuel-sensing enzyme, regulates the metabolic effects of various hormones. Neurotensin (NT) is a 13-amino acid peptide predominantly localized in enteroendocrine cells of the small bowel and released by fat ingestion. Increased fasting plasma levels of pro-NT (a stable NT precursor fragment produced in equimolar amounts relative to NT) are associated with an increased risk of diabetes, cardiovascular disease, and mortality; however, the mechanisms regulating NT release are not fully defined. We previously reported that inhibition of the mammalian target of rapamycin (mTOR) complex 1 (mTORC1) increases NT secretion and gene expression through activation of the MEK/ERK pathway. Here, we show that activation of AMPK increases NT secretion from endocrine cell lines (BON and QGP-1) and isolated mouse crypt cells enriched for NT-positive cells. In addition, plasma levels of NT increase in mice treated with 5-aminoimidazole-4-carboxamide riboside, a pharmacologic AMPK activator. Small interfering RNA-mediated knockdown of AMPKα decrease, whereas overexpression of the subunit significantly enhances, NT secretion from BON cells treated with AMPK activators or oleic acid. Similarly, small interfering RNA knockdown of the upstream AMPK kinases, liver kinase B1 and Ca2+ calmodulin-dependent protein kinase kinase 2, also attenuate NT release and AMPK phosphorylation. Moreover, AMPK activation increases NT secretion through inhibition of mTORC1 signaling. Together, our findings show that AMPK activation enhances NT release through inhibition of mTORC1 signaling, thus demonstrating an important cross talk regulation for NT secretion.

    AB - AMP-activated protein kinase (AMPK), a critical fuel-sensing enzyme, regulates the metabolic effects of various hormones. Neurotensin (NT) is a 13-amino acid peptide predominantly localized in enteroendocrine cells of the small bowel and released by fat ingestion. Increased fasting plasma levels of pro-NT (a stable NT precursor fragment produced in equimolar amounts relative to NT) are associated with an increased risk of diabetes, cardiovascular disease, and mortality; however, the mechanisms regulating NT release are not fully defined. We previously reported that inhibition of the mammalian target of rapamycin (mTOR) complex 1 (mTORC1) increases NT secretion and gene expression through activation of the MEK/ERK pathway. Here, we show that activation of AMPK increases NT secretion from endocrine cell lines (BON and QGP-1) and isolated mouse crypt cells enriched for NT-positive cells. In addition, plasma levels of NT increase in mice treated with 5-aminoimidazole-4-carboxamide riboside, a pharmacologic AMPK activator. Small interfering RNA-mediated knockdown of AMPKα decrease, whereas overexpression of the subunit significantly enhances, NT secretion from BON cells treated with AMPK activators or oleic acid. Similarly, small interfering RNA knockdown of the upstream AMPK kinases, liver kinase B1 and Ca2+ calmodulin-dependent protein kinase kinase 2, also attenuate NT release and AMPK phosphorylation. Moreover, AMPK activation increases NT secretion through inhibition of mTORC1 signaling. Together, our findings show that AMPK activation enhances NT release through inhibition of mTORC1 signaling, thus demonstrating an important cross talk regulation for NT secretion.

    UR - http://www.scopus.com/inward/record.url?scp=84953282821&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84953282821&partnerID=8YFLogxK

    U2 - 10.1210/me.2015-1094

    DO - 10.1210/me.2015-1094

    M3 - Article

    C2 - 26528831

    AN - SCOPUS:84953282821

    VL - 30

    SP - 26

    EP - 36

    JO - Molecular Endocrinology

    JF - Molecular Endocrinology

    SN - 0888-8809

    IS - 1

    ER -